{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '33', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Posttreatment', 'Notes', 'Safety', 'Survival', 'Treatment', 'Follow-', 'Follow-', 'Follow-', 'All procedures are to', 'Study Period', 'Screening', 'Cycle = 21 Days', 'EOT', 'up', 'up', 'up', 'be performed before', '30 Days', 'study intervention', 'At', '-28 to -1', '2', '3', '4', '5', '6 to 35', 'Every', 'Every', 'Visit Timing/', '1', 'DC', 'post last', 'administration unless', '12 weeks', '12 weeks', 'Cycle Number', 'dose', 'otherwise indicated.', 'Cycle Day', 'Refer to Section 8.11', '(=3 days unless', '1', '8', '15', '1', '15', '1', '1', '1', '1', '-', 'for visit details.', 'otherwise specified)', 'Scheduling Window', '+3', '3', '3', '3', '3', '3', '3', '3', '3', '+7', '7', '14', '(Days)', 'Efficacy Procedures', '-All anticancer therapy', 'will be recorded until', 'time of death or', 'termination of survival', 'Subsequent', 'X', 'X', 'X', 'X', 'follow-up.', 'antineoplastic', '-If a clinic visit is not', 'therapy status', 'feasible, follow-up', 'information may be', 'obtained via telephone or', 'e-mail.', 'Participants may be', 'contacted for survival', 'Survival status', 'X', 'status at any time during', 'the course of the study.', 'Tumor Tissue Collection', '-May use archival tissue', 'sample obtained before', 'Newly', 'obtained/archival', 'screening period as part', 'X', \"of the participant's SOC.\", 'tissue sample for PD-', '-Central PD-L1 result', 'L1 analysis', 'will be blinded to the', 'site.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '34', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Posttreatment', 'Notes', 'Safety', 'Survival', 'Treatment', 'Follow-', 'Follow-', 'Follow-', 'All procedures are to', 'Study Period', 'Screening', 'Cycle = 21 Days', 'EOT', 'up', 'up', 'up', 'be performed before', '30 Days', 'study intervention', 'At', '-28 to -1', '1', '2', '3', '4', '6 to 35', 'Every', 'Every', 'Visit Timing/', '5', 'DC', 'post last', 'administration unless', '12 weeks', '12 weeks', 'Cycle Number', 'dose', 'otherwise indicated.', 'Cycle Day', 'Refer to Section 8.11', '(=3 days unless', '1', '8', '15', '1', '15', '1', '1', '1', '1', 'for visit details.', 'otherwise specified)', 'Scheduling Window', '+3', '3', '3', '3', '3', '3', '3', '3', '3', '+7', ' 7', '14', '(Days)', '-Not required for', 'participants with', 'squamous histology or', 'K-ras mutation.', 'EGFR, ALK, and', 'ROSI molecular', '-May send tumor tissue', 'X', 'to central laboratory for', 'status', 'molecular testing if', 'status is unknown and', 'cannot be determined', 'locally.', 'All screening', 'procedures should be', 'Clinical Procedures/Assessments', 'performed within', '28 days of', 'randomization, unless', 'otherwise noted.', 'Full physical', '*To be performed within', 'X*', 'X', 'examination', '7 days before start of', 'study intervention.', 'Directed physical', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'examination', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}